8.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
8.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
8.6 Global Orphan Diseases Market - Opportunity Analysis Index,
By Type,
By Treatment,
By End-user,
and Region, 2024 - 2031
9. North America Global Orphan Diseases Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
9.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.1.1 Genetic Disorders
9.1.2 Rare Cancers
9.1.3 Rare Neurological Diseases
9.1.4 Others
9.2 By Treatment Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.2.1 Gene Therapy
9.2.2 Monoclonal Antibodies
9.2.3 Enzyme Replacement Therapy
9.2.4 Others
9.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Research Institutes.
9.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.4.1 United States
9.4.2 Canada
9.5 North America
Global Orphan Diseases Market – Opportunity Analysis Index,
By Type,
By Treatment,
By End-user,
and Country, 2024 - 2031
9.6 Regional Trends Analysis
9.7 North America Global Orphan Diseases Market Research Report - Company Profiles
9.7.1 Company 1 (United States)
9.7.2 Company 2 (Canada)
9.7.3 Company 3 (Canada)
10. Europe Global Orphan Diseases Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
10.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.1.1 Genetic Disorders
10.1.2 Rare Cancers
10.1.3 Rare Neurological Diseases
10.1.4 Others
10.2 By Treatment Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.2.1 Gene Therapy
10.2.2 Monoclonal Antibodies
10.2.3 Enzyme Replacement Therapy
10.2.4 Others
10.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.3.1 Hospitals
10.3.2 Clinics
10.3.3 Research Institutes.
10.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.4.1 Germany
10.4.2 United Kingdom
10.4.3 France
10.4.4 Spain
10.4.5 Italy
10.4.6 Russia
10.4.7 Netherlands
10.4.8 Poland
10.4.9 Rest of Europe
10.5 Europe
Global Orphan Diseases Market – Opportunity Analysis Index,
By Type,
By Treatment,
By End-user,
and Country, 2024 - 2031
10.6 Regional Trends Analysis
10.7 Europe Global Orphan Diseases Market Research Report - Company Profiles
10.7.1 Company 1 (Germany)
10.7.2 Company 2 (United Kingdom)
10.7.3 Company 3 (United Kingdom)
11. Asia-Pacific Global Orphan Diseases Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
11.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.1.1 Genetic Disorders
11.1.2 Rare Cancers
11.1.3 Rare Neurological Diseases
11.1.4 Others
11.2 By Treatment Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.2.1 Gene Therapy
11.2.2 Monoclonal Antibodies
11.2.3 Enzyme Replacement Therapy
11.2.4 Others
11.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.3.1 Hospitals
11.3.2 Clinics
11.3.3 Research Institutes.
11.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Australia & NZ
11.4.6 ASEAN
11.4.7 Rest of Asia-Pacific
11.5 Asia-Pacific
Global Orphan Diseases Market – Opportunity Analysis Index,
By Type,
By Treatment,
By End-user,
and Country, 2024 - 2031
11.6 Regional Trends Analysis
11.7 Asia-Pacific Global Orphan Diseases Market Research Report - Company Profiles
11.7.1 Company 1 (China)
11.7.2 Company 2 (Japan)
11.7.3 Company 3 (Japan)
12. Latin America Global Orphan Diseases Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
12.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.1.1 Genetic Disorders
12.1.2 Rare Cancers
12.1.3 Rare Neurological Diseases
12.1.4 Others
12.2 By Treatment Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.2.1 Gene Therapy
12.2.2 Monoclonal Antibodies
12.2.3 Enzyme Replacement Therapy
12.2.4 Others
12.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.3.1 Hospitals
12.3.2 Clinics
12.3.3 Research Institutes.
12.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.4.1 Brazil
12.4.2 Mexico
12.4.3 Argentina
12.4.4 Peru
12.4.5 Colombia
12.4.6 Rest of Latin America
12.5 Latin America
Global Orphan Diseases Market – Opportunity Analysis Index,
By Type,
By Treatment,
By End-user,
and Country, 2024 - 2031
12.6 Regional Trends Analysis
12.7 Latin America Global Orphan Diseases Market Research Report - Company Profiles
12.7.1 Company 1 (Brazil)
12.7.2 Company 2 (Mexico)
12.7.3 Company 3 (Mexico)
13. Middle East & Africa Global Orphan Diseases Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
13.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.1.1 Genetic Disorders
13.1.2 Rare Cancers
13.1.3 Rare Neurological Diseases
13.1.4 Others
13.2 By Treatment Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.2.1 Gene Therapy
13.2.2 Monoclonal Antibodies
13.2.3 Enzyme Replacement Therapy
13.2.4 Others
13.3 By End-user Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.3.1 Hospitals
13.3.2 Clinics
13.3.3 Research Institutes.
13.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.4.1 Saudi Arabia
13.4.2 UAE
13.4.3 South Africa
13.4.4 Egypt
13.4.5 Israel
13.4.6 Rest of Middle East and Africa
13.5 Middle East & Africa
Global Orphan Diseases Market – Opportunity Analysis Index,
By Type,
By Treatment,
By End-user,
and Country, 2024 - 2031
13.6 Regional Trends Analysis
13.7 Middle East & Africa Global Orphan Diseases Market Research Report - Company Profiles
13.7.1 Company 1 (Saudi Arabia)
13.7.2 Company 2 (UAE)
13.7.3 Company 3 (UAE)
14. Competition Landscape
14.1 Strategic Dashboard of Top Market Players
14.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
14.2.1 AbbVie Inc.
14.2.2 Alexion Pharmaceuticals Inc.
14.2.3 Amgen Inc.
14.2.4 Biogen Inc.
14.2.5 Bristol-Myers Squibb Company
14.2.6 F. Hoffmann-La Roche AG
14.2.7 Jazz Pharmaceuticals Plc
14.2.8 Johnson & Johnson
14.2.9 Merck & Co. Inc.
14.2.10 Novartis AG
14.2.11 Pfizer Inc.
14.2.12 Sanofi S.A.
14.2.13 Takeda Pharmaceutical Company Limited
14.2.14 Teva Pharmaceutical Industries Ltd.
15. Data Collection Method and Research Approach 16. Principal Presumptions and Acronyms
Methodology & Credibility
Built for enterprise decisions, not vanity metrics.
Triangulated Sizing
Bottom-up, top-down, and peer benchmarks reconciled by analysts.
Primary + Secondary Research
Executive interviews combined with validated public and paid sources.
Scenario & Sensitivity
Base, bull and bear cases to stress-test strategic moves.
Need Confidence Fast?
We’ll map your questions to the report in 15 minutes.